Differential patient selection for amyloid‐targeting immunotherapies in Alzheimer’s disease
Jurij Rosen, Frank Jessen · 2025
Read Differential patient selection for amyloid‐targeting immunotherapies in Alzheimer’s disease by Jurij Rosen, Frank Jessen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11710379.txt.
Description
Jurij Rosen and Frank Jessen test who truly qualifies for new Alzheimer therapies in a 2025 study. Antibody drugs that clear amyloid now offer hope in early disease. Trial entry rules are strict, though, and real patients may not match. The team check a large real-world dataset against those rules.
The dataset held over forty thousand patients, with post-mortem brain reports for a subset. Among those, 887 had a memory-led Alzheimer syndrome at first visit. Trial rules from three drugs left small eligible groups. The authors then check how many of those truly had Alzheimer pathology at death. The study shows how narrow the door to these drugs is in practice.
Catalog record
| CREATOR | Jurij Rosen, Frank Jessen |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |